The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...
Please provide your email address to receive an email when new articles are posted on . The framework centers on clinical, imaging, biomarker and external influences on TBI. The framework can be ...
For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...
OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...
ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...
BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for ...
NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience ...
We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving adults with acute, nonarteritic central retinal artery occlusion who had symptom onset within 4.5 hours ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced debut data from its Phase 3 ALLEVIATE-1 and ALLEVIATE-2 studies evaluating the safety and efficacy of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results